| Excerpt | Relevance | Reference |
|---|
| "Rivaroxaban, a highly selective direct factor Xa inhibitor, is a new oral anticoagulant approved by the US Food and Drug Administration in November 2011 for stroke prophylaxis in patients with nonvalvular atrial fibrillation." | 7.83 | Severe jaundice due to intrahepatic cholestasis after initiating anticoagulation with rivaroxaban. ( Akçay, M; Aslan, AN; Baştuğ, S; Bozkurt, E; Durmaz, T; Sari, C; Sari, SÖ, 2016) |
| "Rivaroxaban, a highly selective direct factor Xa inhibitor, is a new oral anticoagulant approved by the US Food and Drug Administration in November 2011 for stroke prophylaxis in patients with nonvalvular atrial fibrillation." | 3.83 | Severe jaundice due to intrahepatic cholestasis after initiating anticoagulation with rivaroxaban. ( Akçay, M; Aslan, AN; Baştuğ, S; Bozkurt, E; Durmaz, T; Sari, C; Sari, SÖ, 2016) |